When profit meets public health: private equity in methadone treatment

• Private equity (PE) owns a growing share of U.S. opioid treatment programs (OTPs). • PE expansion is linked to distinctive methadone regulations and public financing changes. • Ownership structure may influence methadone access, costs, and patient outcomes. • Nascent research agenda on OTP ownership can inform policy response. Opioid overdose deaths in the U.S. exceed 80,000 annually and methadone, an effective treatment for opioid use disorder (OUD), remains difficult to access. Understanding how ownership structures affect access, quality, cost, and regulation in methadone treatment for opioid use disorder in the U.S. is thus a public health imperative. Private equity (PE) has rapidly consolidated opioid treatment programs (OTPs), now owning nearly one-third of all facilities that are the primary means for receiving methadone treatment. This growth is rooted in a complex federal regulatory regime and public-financing expansions that create barriers for smaller providers and predictable revenue streams for PE-owned facilities. While proponents of PE tout their capacity to infuse capital and modernize care, emerging evidence — combined with concerning patterns from PE ownership in other health sectors — suggests risks of understaffing, aggressive revenue optimization, and regulatory influence. This commentary highlights the mechanisms through which ownership may influence care and outlines a research and policy agenda to ensure financial structures advance, rather than undermine, equitable and effective OUD treatment.